Theriva Biologics Announces Sale Of Antibiotic-Degrading Enzyme Portfolio To Biossil For $350K Upfront, Up To $91M In Milestones, Plus Royalties
Share
Why It Matters
Theriva sold a technology that breaks down antibiotics to another company. They got money now and could earn much more if it succeeds.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.